Zhengye Biotechnology Regains Nasdaq Compliance, Removing Delisting Risk
ZYBT has more than doubled off its 52-week low of $0.616.
Summary
Zhengye Biotechnology regained Nasdaq compliance after its stock price held above $1.00 for 10 consecutive days, eliminating the delisting threat that had been hanging over the company since June.
Key Events · Corporate Governance and Compliance · ZYBT
-
Nasdaq Compliance Regained
Nasdaq confirmed on August 5, 2026 that Zhengye Biotechnology has regained compliance with the minimum bid price rule after its stock closed at or above $1.00 for 10 consecutive business days (July 20 – August 4, 2026).
-
Delisting Risk Removed
The compliance confirmation closes out the deficiency notice received on May 29, 2026, which had given the company until November 25, 2026 to cure. The stock now trades at $2.18, well above the $1.00 threshold.
-
Listing Status Preserved
The company remains listed on the Nasdaq Capital Market under ticker ZYBT, maintaining access to U.S. equity markets and avoiding the stigma and liquidity impact of a potential delisting.
Analysis · ZYBT · Life Sciences
Zhengye Biotechnology has regained compliance with Nasdaq's minimum bid price rule, closing out a deficiency that threatened its listing. The stock traded above $1.00 for 10 consecutive business days from July 20 to August 4, 2026, and Nasdaq confirmed compliance on August 5. This removes the immediate delisting overhang and preserves access to U.S. capital markets, a critical outcome for a small-cap Chinese veterinary vaccine maker that faced a compliance deadline of November 25, 2026.
At the time of this filing, ZYBT was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.1M. The 52-week trading range was $0.62 to $13.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.